Antengene Email Format

Pharmaceutical ManufacturingShanghai, China51-200 Employees

Antengene is a Shanghai-based pharmaceutical manufacturing company focused on discovery, development, manufacturing and commercialization of therapeutics for hematologic malignancies and solid tumors. It is a global, R&D-driven, commercial-stage biotech company with a pipeline of nine oncology programs spanning clinical to commercial stages, including six with global rights and three with APAC rights. Its lead commercial asset, XPOVIO (selinexor), has approvals in Mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. In 2026, Antengene entered into a strategic collaboration with Junshi Biosciences to evaluate the combination of Junshi's JS207 with Antengene's ATG-037 in solid tumors in Mainland China. In 2025, ATG-022, Antengene's CLDN18.2 ADC, received Breakthrough Therapy designation from the NMPA for CLDN18.2-positive gastric/GEJ cancer; the program is in Phase II dose-expansion in China and Australia. The company is headquartered in Shanghai, China, and employs 51-200 people.

Sign up for free to view info

Company overview Employee directory